Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas

(2015) Marco Losa et al.   JOURNAL OF NEURO-ONCOLOGY

Glioblastoma Multiforme Metastasis Outside the CNS: Three Case Reports and Possible Mechanisms of Escape

(2014) Jackson D. Hamilton et al.   JOURNAL OF CLINICAL ONCOLOGY

A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up

(2013) Jacqueline Trouillas et al.   ACTA NEUROPATHOLOGICA

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

(2013) Robert L. Fine et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)

(2013) Brad E. Zacharia et al.   NEUROSURGERY

Treatment of Multiple Endocrine Neoplasia 1/2 Tumors: Case Report and Review of the Literature

(2012) Anthony P. Gulati et al.   ONCOLOGY

Pituitary Carcinoma: Difficult Diagnosis and Treatment

(2011) Anthony P. Heaney   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Silent subtype 3 carcinoma of the pituitary: a case report

(2009)   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor

(2009) Marie S. Thearle et al.   Pituitary